I have about a 10% position in MESO vs CYDY. This news makes me both proud and nervous. Proud that leronlimab indeed could be the last mab standing. Nervous because it is becoming more and more evident that s/c population and mortality endpoint is a very very difficult accomplishment. That's exacerbated by the increasing quality of SOC, which MESO seemed to have fallen into. Their pilot data suggested a high efficacy; their 2 previous interim looks suggested being on track to meet endpoint. This partly mirrors leronlimab's experience (positive eINDs and unchanged interim checks) but failed by 3rd interim check. I still believe we will hit the needed outcome but just a little nervous seeing how high the mountain has become.

"MESO just failed in COVID-19"